Nektar Therapeutics (NKTR) Tops Q4 EPS by 2c
Tweet
Share
E-mail
Get Alerts NKTR Hot Sheet
Price: $71.04 --0%
EPS Growth %: +26.6%
Financial Fact:
Total revenue: 36.34M
Today's EPS Names:
CRMT, PKE, More
EPS Growth %: +26.6%
Financial Fact:
Total revenue: 36.34M
Today's EPS Names:
CRMT, PKE, More
Join SI Premium – FREE
Nektar Therapeutics (NASDAQ: NKTR) reported Q4 EPS of ($0.79), $0.02 better than the analyst estimate of ($0.81). Revenue for the quarter came in at $25 million versus the consensus estimate of $25.33 million.
For earnings history and earnings-related data on Nektar Therapeutics (NKTR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Trump said he was unaware of his earnings from crypto
- Clarivate to sell life sciences unit to Altaris for $600 million
- Raymond James Downgrades Delta Air Lines (DAL) to Outperform
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
